Neointimal response to second-generation drug-eluting stents in diabetic patients with de-novo coronary lesions: Intravascular ultrasound study

Hoyoun Won, Tae Soo Kang, Bum Kee Hong, Seunghwan Lee, Dong Woon Jeon, Sung Kee Ryu, Pil Ki Min, Young Won Yoon, Byoung Kwon Lee, Hyuck Moon Kwon, Young Guk Ko, Yangsoo Jang

Research output: Contribution to journalArticle

2 Citations (Scopus)


Objectives The aim of this study was to evaluate the extent of neointimal response after the implantation of a second-generation drug-eluting stent, zotarolimus-eluting stent (ZES-ER, Endeavor Resolute) or everolimus-eluting stent (EES, Xience V), using intravascular ultrasound (IVUS) in diabetic patients. Materials and methods In all, 154 diabetic patients with de-novo coronary lesions were randomized to be implanted with a ZES-ER or EES, and the angiographic follow-up at 9 months combined with a complete IVUS study was available for 96 patients with 101 lesions. Results Baseline demographic and lesion parameters were similar in both groups at index percutaneous coronary intervention. On follow-up angiography, in-stent late lumen loss and minimal lumen diameter were not different between the two groups. On IVUS study, neointimal hyperplasia volume [median (interquartile range): ZES-ER vs. EES; 2.25 mm 3 (0.57-6.25) vs. 1.59 mm 3 (0.45-8.37), P=0.615] and in-stent percentage of volume obstruction [median (interquartile range): ZES-ER vs. EES; 1.16% (0.33-3.61) vs. 0.77% (0.29-4.01), P=0.615] showed similar results between the two groups. Conclusion In diabetic patients, the second-generation drug-eluting stents, ZES-ER and EES, were comparable in inhibiting neointimal proliferation.

Original languageEnglish
Pages (from-to)212-219
Number of pages8
JournalCoronary artery disease
Issue number3
Publication statusPublished - 2015 Apr 22


All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this